Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant Plasmodium falciparum

• Autors principals: Kun Zhang (Autor), Yu Zhao (Autor), Zheng Zhang (Autor), Mengyao Zhang (Autor), Xiaodong Wu (Autor), Huijie Bian (Autor), Ping Zhu (Autor), Zhinan Chen (Autor)
• Format: Llibre
• Publicat: Elsevier, 2020-09-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Meplazumab is an anti-CD147 humanized IgG2 antibody. The purpose of this study was to characterize the nonclinical safety, tolerance and efficacy evaluation of meplazumab treating chloroquine resistant Plasmodium falciparum. Meplazumab was well tolerated in repeat-dose toxicology studies in cynomolg...